CytoDyn Inc.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CytoDyn, Inc. is a clinical-stage biotechnology company, which focuses on the clinical development of innovative treatments for multiple therapeutic indications based on its product candidate, leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5. Its pipeline includes Leronlimab Clinical Development Pipeline and Long-Acting CCR5 Inhibitor Development Pipeline. The company was founded by Allen D. Allen on May 2, 2002 and is headquartered in Vancouver, WA.

NEW YORK--(BUSINESS WIRE)--A group of long-time stockholders (the “Nominating Stockholders” or the “Group”) of CytoDyn Inc. (“CYDY or the “Company”) (OTC: CYDY) that has nominated five highly experienced director candidates to serve on the Company's Board of Directors today released a white paper regarding CYDY's unfavorable borrowing practices. The white paper highlights that in particular, since the June of 2018, CYDY has borrowed a sizable portion of its operating capital from Iliad Research

Group of CytoDyn Stockholders Releases White Paper Regarding Company's Extremely Unfavorable Borrowing Practices

VANCOUVER, Wash.--(BUSINESS WIRE)--CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer and Scott Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development of CytoDyn will provide a comprehensive business update at the upcoming Emerging Growth Conference. CytoDyn

CytoDyn to Present at Emerging Growth Conference on September 29 Followed by Live Q/A

Clear Channel Outdoor Holdings

IAMGOLD

Are these penny stocks on your September watchlist? The post Making a Penny Stocks Watchlist in October?

Making a Penny Stocks Watchlist in October? Check These 3 Out

NEW YORK--(BUSINESS WIRE)--A group of long-time stockholders (the “Nominating Stockholders” or the “Group”) of CytoDyn Inc. (“CYDY or the “Company”) (OTC: CYDY) that has nominated five highly experienced director candidates to serve on the Company's Board of Directors today announced its comprehensive strategic plan to obtain cancer therapy approval for Leronlimab. If implemented, the Group believes this plan would begin to generate much-needed revenue for CYDY and position the Company to earn

Group of CytoDyn Stockholders Shares Strategic Plan to Obtain Cancer Therapy Approval for Leronlimab

CytoDyn Inc revealed that Brazil's regulatory authority Agência Nacional de Vigilância Sanitária (ANVISA) has approved the start of an additional Phase 3 CD16 clinical trial of its flagship drug leronlimab to treat critically ill coronavirus (COVID-19) patients. The Vancouver, Washington-based late-stage biotechnology company said the new clinical trial will focus on hospitalized COVID-19 patients in critical condition who require mechanical and invasive ventilation or Extracorporeal Membrane Oxygenation (ECMO).

CytoDyn says Brazil approves pivotal Phase 3 clinical trial of leronlimab in critically ill coronavirus patients

VANCOUVER, Wash.--(BUSINESS WIRE)--CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that Brazil's regulatory authority, ANVISA (Agência Nacional de Vigilância Sanitária), has approved the start of an additional Phase 3 CD16 clinical trial of leronlimab. The new clinical trial will focus on hospitalized COVID-19 patients in critical conditio

CytoDyn Receives Clearance from Brazil's FDA (ANVISA) to Commence a Pivotal Phase 3 Trial in Critically Ill COVID-19 Patients with IV Administration of Four Doses (700mg/week)

VANCOUVER, Wash.--(BUSINESS WIRE)--CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that Dr. Scott Kelly, CytoDyn's Chairman of the Board, Chief Medical Officer and Head of Business Development, will be presenting at the World Antiviral Congress 2021. The Congress will be held from November 30 – December 2, 2021, in San Diego. Dr. Kelly wil

CytoDyn's Chairman, CMO, and Head of Business Development Dr. Scott A. Kelly to Present at the World Antiviral Congress 2021

NEW YORK--(BUSINESS WIRE)--A group of long-time stockholders (the “Nominating Stockholders” or the “Group”) of CytoDyn Inc. (“CYDY or the “Company”) (OTC: CYDY) that has nominated five highly experienced director candidates to serve on the Company's Board of Directors today announced that Judge Maryellen Noreika has approved a joint stipulation to dismiss CYDY's lawsuit in the United States District Court for the District of Delaware. The litigation, which related to disclosures by the Nominati

Group of CytoDyn Stockholders Announces Federal Court Dismisses Litigation Brought by Company

BEST Inc - ADR

Virpax Pharmaceuticals

Penny stocks bouncing back after the stock market sell-off The post Best Penny Stocks To Buy Today? Retail Traders Are Watching These Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks To Buy Today? Retail Traders Are Watching These Now

VANCOUVER, Wash.--(BUSINESS WIRE)--The Board of Directors (the “Board”) of CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced the resolution of its lawsuit (the “Federal Lawsuit”) brought in the United States District Court for the District of Delaware against the activist group led by Paul Rosenbaum and Bruce Patterson (the “Rosenbaum/Patter

CytoDyn Announces Resolution of Federal Litigation with Rosenbaum/Patterson Activist Group

NEW YORK--(BUSINESS WIRE)--A group of long-time stockholders (the “Nominating Stockholders”) of CytoDyn Inc. (“CYDY or the “Company”) (OTC: CYDY) that has nominated five highly experienced director candidates to serve on the Company's Board of Directors today announced that Bruce Patterson, M.D., one of the candidates, attended and presented at the International COVID Summit, held in Rome, Italy from September 12-14, 2021. The summit was a gathering of world-renowned medical researchers and sci

Bruce Patterson, M.D., Director Candidate for CytoDyn Board, Presents at International COVID Summit

NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of CytoDyn Inc. (OTCQB:CYDY) concerning the Company and its directors' and officers' possible violations of state laws. If you purchased CytoDyn Inc. stock, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Tom Kennedy of GPM, 230 Park Avenue, Suite 358, New York, NY 10169, at tkenne

Glancy Prongay & Murray LLP Announces Investigation of CytoDyn Inc.

VANCOUVER, Washington, Sept. 13, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer and Scott Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development of CytoDyn will provide a comprehensive business update at the upcoming Emerging Growth Conference. CytoDyn will present for 20 minutes, and 40 minutes will be dedicated to live questions and answers.

CytoDyn to Present at Emerging Growth Conference on September 15 Follow by Live Q/A

CytoDyn Inc has announced the treatment of the first patient with its flagship drug candidate leronlimab (Vyrologix or PRO 140) in a pivotal Phase 3 coronavirus (COVID-19) trial in Brazil for patients with severe symptoms.  The Vancouver, Washington-based late-stage biotechnology company said an interim analysis will be conducted 28 days following the enrollment of 245 patients, which is 40% of the total number of patients to be enrolled in the trial.

CytoDyn treats the first patient with leronlimab in its Pivotal Phase 3 coronavirus trial in Brazil for patients with severe symptoms

An interim analysis will be conducted 28 days following enrollment of 245 patients (40% of targeted trial patients)

CytoDyn Announces Treatment of the First Patient in its Pivotal Phase 3 COVID-19 Trial in Brazil for Patients with Severe Symptoms

NEW YORK--(BUSINESS WIRE)--A group of long-time stockholders (the “Nominating Stockholders”) of CytoDyn Inc. (“CYDY” or the “Company”) (OTC: CYDY) that has nominated five highly experienced director candidates to serve on the Company's Board of Directors today responded to a news release issued by CYDY on September 3, 2021 that completely misrepresented a voluntary stipulation filed by the Nominating Stockholders in the litigation initiated by the Company in the United States District Court. Th

Group of CytoDyn Stockolders Responds to Misleading Company News Release

VANCOUVER, Washington, Sept. 02, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development, and Christopher Recknor, M.D., Chief Operating Officer and Head of Clinical Development, will host an investment community webcast on Wednesday, September 8, 2021.

CytoDyn to Hold Webcast on September 8 to Discuss Results from mTNBC Trials, HIV BLA Status, and Updates on COVID-19 and NASH Trials

VANCOUVER, Wash.--(BUSINESS WIRE)--The Board of Directors (the “Board”) of CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today issued a statement to shareholders commenting on the Court Order entered yesterday by a United States District Court Judge in the lawsuit brought by CytoDyn against the activist group led by Paul Rosenbaum and Bruce Patterson (t

CytoDyn Highlights Court Ordering Rosenbaum/Patterson Group to Comply With the Federal Securities Laws

NEW YORK--(BUSINESS WIRE)--A group of long-time stockholders (the “Group”) of CytoDyn Inc. (“CYDY” or the “Company”) (OTC: CYDY) that has nominated five highly experienced director candidates to serve on the Company's Board of Directors today released a letter to fellow stockholders outlining recent ill-advised actions and announcements made by CYDY's current leadership that have further destroyed the Company's value and damaged its credibility. The letter outlines CYDY leadership's previous un

Group of CytoDyn Stockholders Warns Stockholders of Board's Continued Value Destruction and Failures

CytoDyn's main product candidate is Vyrologix, an injectable antibody that shows promise as an anti-viral agent The company is preparing to release data from a Phase 2b/3 coronavirus study Two Phase 3 HIV trials have been completed What CytoDyn does: CytoDyn Inc (OTCMKTS:CYDY), a Vancouver, Washington-based late-stage biotechnology company, is developing Vyrologix (leronlimab or PRO 140) to battle multiple diseases. Most significantly, it is working to develop a significant advance in HIV treatment beyond the “AIDS cocktail” combination of pills that has kept millions of people alive since the mid-1990s.

CytoDyn has multiple shots on goal with its flagship drug Vyrologix to treat for HIV, various cancers and even coronavirus

CytoDyn Inc has announced the appointment of Seenu Srinivasan as the company's new executive director of chemistry, manufacturing, and controls (CMC) Regulatory Affairs.  Srinivasan, a former director of CMC Regulatory Affairs for Regeneron Pharmaceuticals Inc, brings 30 years of broad regulatory and drug development experience to his role at CytoDyn, including extensive CMC experience in developing active pharmaceutical ingredients (APIs) and drug products from early phase to commercialization.

CytoDyn appoints pharma industry veteran Seenu Srinivasan as its executive director of CMC Regulatory Affairs

Dr. Srinivasan provides 30 years of broad regulatory and drug development experience including a career serving as Director of CMC Regulatory Affairs for Regeneron Pharmaceuticals, Inc. where he led the CMC strategy and successfully submitted a monoclonal antibody based BLA (Dupixent approved in 2017)

CytoDyn Appoints Seenu Srinivasan, Ph.D. as Executive Director of CMC Regulatory Affairs

NEW YORK--(BUSINESS WIRE)--A group of long-time stockholders (the “Group”) of CytoDyn Inc. (“CYDY or the “Company) (OTC: CYDY) that has nominated five highly experienced director candidates to serve on the Company's Board of Directors today announced that it has filed a lawsuit in the Delaware Court of Chancery seeking to force CYDY to allow stockholders to vote for the Group's nominees. CYDY has previously filed litigation seeking to block the ability of stockholders to vote for the Group's no

Group of CytoDyn Stockholders Files Lawsuit to Force Company to Allow Stockholders to Vote for Alternative Director Nominees

CytoDyn Inc shared an update to its previously reported preliminary results from its Phase 1b/2 trials and compassionate use of its flagship drug candidate leronlimab to treat a total of 30 metastatic triple-negative breast cancer (mTNBC) patients. The Vancouver, Washington-based late-stage biotechnology company said that decrease in circulating tumor cells (CTC) as reported using the LifeTracDx test developed by Creatv MicroTech Inc, after induction with leronlimab was associated with a 400%-to-660% increase in modified progression free Survival (mPFS), 12-month Progression Free Survival (PFS) and a 570%-to-980% increase in modified overall survival (mOS), and 12-month overall survival.

CytoDyn says its final mTNBC report shows 980% increase in 12-month overall survival with its flagship drug leronlimab

VANCOUVER, Wash.--(BUSINESS WIRE)--The Board of Directors (the “Board”) of CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today issued the following statement to shareholders: “Shareholders may have received proxies from the activist group led by Paul Rosenbaum and Bruce Patterson (the “Rosenbaum/Patterson Group” or the “Group”) seeking your votes to tak

News for CytoDyn Inc. Stock (CYDY)